Pharmaceuticals & Biotechnology
Key highlights
- Indian Pharmaceuticals & Biotechnology demand remains supported by chronic-care penetration, domestic branded formulations, export opportunities, semaglutide launches and biosimilar adoption.
- Q2 FY27 results show strong domestic-formulation execution at Mankind, Eris and several smaller companies, while Dr. Reddy’s North America revenue remained affected by lower lenalidomide sales.
- Margin expansion is being driven by product mix, operating leverage, higher-value launches and recovery in selected API markets; ibuprofen remains structurally volatile.
- Complex generics, controlled substances, peptides, oncology, biosimilars and cell therapies are becoming key investment areas across Granules, Dr. Reddy’s, Mankind, Eris and Beta Drugs.
- Regulatory execution remains the principal valuation risk for export-oriented manufacturers, particularly companies managing USFDA observations, remediation programmes or plant reinspection requirements.
- Policy support through Biopharma SHAKTI, BioE3, PLI schemes, bulk-drug infrastructure and clinical-trial expansion supports the sector’s long-term transition toward higher-value pharmaceutical manufacturing.
powered by IRIS
Unlock full access to this sectoral analysis with in-depth insights, comprehensive data, and exclusive reports.


